Loading...
 
Back to the list
Mediterr J Rheumatol 2020;31(Supp 2):275-83
Article Links
COVID-19: An Archetype Innate Immunity Reaction and Modes of Treatment
Periklis Vounotrypidis
Authors Information

Rheumatology Department, 424 General Military Hospital, Thessaloniki, Greece

Periklis Vounotrypidis

Keywords: SARS-CoV-2, rheumatology, hyperferritinaemia, immunotherapy, corticosteroids, disease-modifying anti-rheumatic drugs
References
  1. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region – Case series. N Engl J Med 2020;382:2012-22.
  2. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance 13 March 2020. (2020). Accessed Apr 12, 2020. https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf  
  3. Salerno M, Sessa F, Piscopo A, Montana A, Torrisi M, Patane F, et al. No autopsies on COVID-19 deaths: A missed opportunity and the lockdown of science. J Clin Med 2020;9:1472.
  4. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamizar-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis Mar-Apr 2020;34:101623.
  5. Wang T, Du Z, Zhu F, Cao Z, An Y, Gao Y, et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020 Mar 21;395(10228):e52.
  6. CDC COVID-19 response team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12 – March 28, 2020. MMWR Morb Mortal Wkly Rep 2020:69:382-6.
  7. Liang WH, Guan WJ, Li CC, Li YM, Liang HR, Zhao Y, et al. Clinical characteristics and outcomes of hospitalized patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicenter): A Nationwide Analysis of China. Eur Respir J 2020 Apr 8. pii:2000562.
  8. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
  9. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA 2020 Mar 23. doi: 10.1001/jama.2020.4683. Online ahead of print.
  10. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. Tob Induc Dis 2020;18:20.
  11. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J 2020 Mar 26. pii:2000547.
  12. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis. Faraway, so close. Autoimmun Rev 2020;19:102523.
  13. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020 Mar 28;395(10229):1054-62.
  14. Smits SL, de Lang A, van den Brand JM, Leijten LM, van IJken MF, Eijkemans MJ, et al. Exacerbated innate host response to SARS-CoV in aged non-human primates. PLoS Pathog 2010 Feb 5;6(2):e1000756.
  15. Goldberg EL, Shaw AC, Montgomery RR. How inflammation blunts innate immunity in ageing. Interdiscip Top Gerontol Geriatr 2020;43:1-17.
  16. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 among children in China. Pediatrics 2020;145:e20200702.
  17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet 2020;395:1033-4.
  18. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020 Mar 20:105949.
  19. Wu C, Chen X, Cai Y. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020:1-10.
  20. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
  21. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015;385:1729-37.
  22. Sartelli M, Kluger Y, Ansaloni L, Hardcastle TC, Rello J, Watkins RR, et al. Raising concerns about the sepsis-3 definitions. World J Emerg Surg 2018 Jan 25;13:6.
  23. Ghnewa YG, Fish M, Jennings A, Carter MJ, Shankar-Hari M. Goodbye SIRS? Innate, trained and adaptive immunity and pathogenesis of organ dysfunction. Med Klin Intensivmed Notfmed 2020 115, p10-4(2020).
  24. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39, p2055-62(2020).
  25. Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med 2020 Apr 23;382(17):e38.
  26. Zulfigar AA, Lorenzo-Villalba N, Hassler P, Andres E. Immune thrombocytopenic purpura in a patient with Covid-19. N Engl J Med 2020 Apr 30;382(18):e43.
  27. Castelnovo L, Capelli F, Tamburello A, Faggioli PM, Mazzone A. Symmetric cutaneous vasculitis in COVID-19 pneumonia. J Eur Acad Dermatol Venereol 2020 Aug;34(8):e362-e363.
  28. Xu S, Chen M, Weng J. COVID-19 and Kawasaki disease in children. Pharmacol Res 2020;159;104951.
  29. Roncati L, Ligabue G, Fabbiani L, Malagoli C, Gallo G, Lusenti B, et al. Type 3 hypersensitivity in COVID-19 vasculitis. Clin Immunol 2020;217:108487.
  30. Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020 Jun 4;382(23):2268-70.
  31. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. Covid-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020;38:175-80.
  32. Peng L, Liu KY, Xue F, Miao YF, Tu PA, Zhou C. Improved early recognition of coronavirus disease-2019 (COVID-19): Single-Center data from a Shanghai screening hospital. Arch Iran Med 2020;23:272-6.
  33. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical feature of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  34. Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020 Jul;92(7):791-6.
  35. Wang W, Knovich MA, Cofman LG, Torti FM, Torti SV. Serum ferritin: Past, present and the future. Biochim Biophys Acta 2020;1800:760-69.
  36. Recalcati S, Invernizz P, Arosio P, Cairo G. New functions for an iron storage protein: The role of ferritin in immunity and autoimmunity. J Autoimmun 2008;30:84-9.
  37. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-,CoV pneumonia. Signal Transduct Target Ther 2020;5:18.
  38. Raghavan M, Marik PE. Management of sepsis during the early “golden hours”. J Emerg Med 2006;31:185-99.
  39. Bogdanos DP, Daniil Z, Zakynthinos E, Gourgoulianis K, Sakkas LI. When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients? Meditter J Rheumatol 2020;31:94-7.
  40. Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020 Mar 4;105932.
  41. Deftereos SG, Siasos G, Giannopoulos G, Vrachatis DA, Angelidis C, Giotaki SG, et al. The Greek study in the effects of colchicines in Covid-19 complications prevention (GRECCO-19 study): Rationale and study design. Hellenic J Cardiol 2020 Apr 3. pii: S1109-9666(20)30061-0.
  42. Leung YY, Yao Hui LL, Kraus VB. Colchicine-Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum 2015;45:341-50.
  43. Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postrgrad Med J 2020;pii: postgradmedj-2020-137785.
  44. Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, et al. Virological and clinical cure in Covid-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis. J Med Virol 2020 Jul;92(7):776-85.
  45. Russel CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473-5.
  46. Torres A, Chalmers JD, Dela Cruz CS, Dominedo C, Kollef M, Martin-Loeches I, et al. Challenges in severe community-acquired pneumonia: a point-of-view review. Intensive Care Med 2019;45:159-71.
  47. Giannitsioti E, Protopapas K, Makris M, Panou F, Avgeropoulou E, Deliolanis I, et al. Is there a place for corticosteroids in the therapy of infective endocarditis? Report of a case and review. Hellenic J Cardiol 2017;58:93-5.
  48. Annane D, Bellisant E, Bollaert PE, Briegel J, Keh D, Kupfer Y, et al. Corticosteroids for treating sepsis in children and adults. Cochrane Database Syst Rev 2019 Dec 6;12:CD002243.
  49. Long B, Koyfman A. Controversies in corticosteroid use for sepsis. J Emerg Med 2017;53:653-661. doi: 10.1016/j.jememed.2017.05.024.
  50. Alhazzani W, Moller MH, Arabi Y, Loeb M, Gong MNg, Fan E, et al. Surviving sepsis campaign: Guidelines on the management of critically ill adults with corovavirus disease 2019 (COVID-19). Crit Care Med 2020;46:854-87.
  51. Solinas C, Perra L, Aiello M, Migliori E, Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine Growth Factor Rev 2020;S1359-6101(20)30161-1.
  52. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective control study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Version 2. Signal Transduct Target Ther 2020;5:57.
  53. National Health Commission of the People’s Republic of China. The 5th trial version of diagnosis and treatment scheme for pneumonitis with 2019-nCoV infection. (2020). Accessed Apr 19, 2020. http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml
  54. Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A personalized diagnostic and treatment approach for macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis in adults. J Clin Immunol 2017;37:638-43.
  55. Shi W, Duan M, Jie L, Sun W. A successful treatment of severe systemic lupus erythematosus caused by occult pulmonary infection associated with hemophagocytic syndrome: A case report. Medicine (Baltimore) 2018;97(19):e0595.
  56. Wampler Muskardin TL. Intravenous anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID19. ACR Open Rheumatol 2020 May;2(5):283-5.
  57. Nosaka N, Martinon D, Moreira D, Crother TR, Arditi M, Shimada K. Autophagy protects against developing increased lung permeability and hypoxemia by down-regulating inflammasome activity and IL-1β in LPS plus mechanical ventilation-induced acute lung injury. Front Immunol 2020 Feb 14;11:207.
  58. Monteagudo LA, Boothby A, Gertner E. Continuous intravenous anakinra infusion to calm the cytokine storm in macrophage activation syndrome. ACR Open Rheumatol 20202:276-82.
  59. Wang R, Li T, Ye S, Tan W, Zhao C, Li Y, et al. Macrophage activation syndrome associated with adult-onset Still’s disease: a multicenter retrospective analysis. Clin Rheumatol 2020 Aug;39(8):2379-86.
  60. Irabu H, Shimizu M, Kaneko S, Inoue N, Mizuta M, Nakagishi Y, et al. Comparison of serum biomarkers for the diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis during tocilizumab therapy. Pediatr Res 2020 Mar 17. doi: 10.1038/s41390-020-0843-4. Online ahead of print.
  61. Chen X, Zhao B, Qu Y, Chen Y, Xiong J, Feng Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020:ciaa449.
  62. Herold T, Jurinovic V, Arnreich C, Lipworth BJ, Hellmuth JC, von Bergwelt-Baildon M, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020;146:128-136.e4.
  63. Watanabe E, Sugawara H, Yamashita T, Ishii A, Oda A, Terai C. Successful tocilizumab therapy for macrophage activation syndrome associated with adult-onset Still’s disease: A case-based review. Case Rep Med 2016;2016:5656320.
  64. Asanuma YF, Mimura T, Tsuboi H, Noma H, Miyoshi F, Yamamoto K, et al. Mod Rheumatol 2015;25:393-400.
  65. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle D, Richardson P. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Inf Dis 2020 Feb 27. pii: S1473-3099(20)30132-8.
  66. Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature. Yale J Biol Med 2020;93:187-95.
  67. Sanchez-Pernaute O, Romero-Bueno FI, Selva-O’Callaghan A. Why choose cyclosporin A as first-line therapy in COVID-19 pneumonia. Rheumatol Clin 2020;S1699-258X(20)30044-9.
  68. Di Altobrando A, Patrizi A, Bardazzi F. Shouls SARS-CoV-2 influence immunosupressive therapy for autoimmune blistering diseases? J Eur Acad Dermatol Venereol 2020;10.1111/jdv.16491.
  69. Khurana A, Saxena S. Immunosuppressive agents for dermatological indications in the ongoing COVID-19 pandemic: Rationalizing use and clinical applicability. Dermatol Ther 2020;e13639.
  70. Cunningham AC, Goh HP, Koh D. Treatment of COVID-10: old tricks for new challenges. Crit Care 2020;24:91.
  71. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA 2020 Apr 6. pii:202004168.
  72. Valk SJ, Piechotta V, Chai KL, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cohrane Database Syst Rev 2020;5:CD013600.
  73. Solaimanzadeh I. Acetazolamide, nifedipine and phosphodiesterase inhibitors: Rationale for their utilization as adjunctive countermeasures in the treatment of coronavirus disease 2019 (COVID-19). Cureus 2020;12:e7343.
  74. Luks AM, Freer L, Grissom CK, McIntosch SE, Schoene RB, Swenson ER, et al. COVID-19 lung injury is not a high alltitude pulmonary oedema. High Altitude Med Biol 2020 Jun;21(2):192-3.
  75. Drosos AA, Pelechas E, Voulgari PV. Treatment strategies are more important than drugs in the management of rheumatoid arthritis. Clin Rheumatol 2020;39:1363-8.
  76. Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe 2020 Apr 17. pii: S1931-3128(20)30236-5.
  77. Gomez R, Maakaron J, Baiocchi R. Macrophage activation syndrome versus Hemophagocytic Lymphohistiocytosis: A diagnostic dilemma in a patient with Still’s disease and Epstein-Barr viremia. J Hematol 2019;8:68-70.
  78. Fautrel B, Zing E, Golmard JL, Le Moel G, Bissery A, Rioux C, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine (Baltimore) 2002;81:194-200.